Skip to content
Study details
Enrolling now

Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders

National Institute of Mental Health (NIMH)
NCT IDNCT00018057ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

2,530

Study length

about 27 years

Ages

8–65

Locations

1 site in MD

What this study is about

This trial is testing how anxiety affects the brain in children. It compares healthy kids and those with anxiety to see if certain brain changes happen before or after treatment. It uses brain scans, tests, and questionnaires to understand these connections.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Participate in Attention Bias Modification Training
  • 2.Take Fluoxetine

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

fluoxetine (SSRI; increases serotonin levels in brain)

Drug routes

oral (Oral Capsule)

Endpoints

Secondary: Another secondary objective is to document relations between post-treatment changes in neurocognitive features and anxiety symptoms on the PARS following treatment with Cognitive Behavioral Therapy (CBT) or fluoxetine.

Body systems

Psychiatry / Mental Health